Mga pasyente sa late-stage cancer ay madalas mayroong symptoms ng qi deficiency at blood stasis. Ang Beijing Cancer Prevention and Treatment Research Institute ay gumawa ng isang pag-aaral tungkol sa epekto ng qi-tonifying at blood-activating therapy kasama ang chemotherapy sa late-stage malignant tumors, kasama ang duration ng tumor survival at quality of life. Ang mga mananaliksik ay nagsabi na para sa mga late-stage malignant tumor na wala na nang root cure, ang chemotherapy kasama ang Tsino medicine, lalo na ang Tsino medicine na base sa pagsusuri, ay napakahalaga.
Ang mga mananaliksik ay pumili ng 61 mga pasyente na may late-stage lung, breast, o colon cancer na diagnosed through histopathology o cytology. Ginamit ang random number table na nilikha ng statistical software para sa random assignment sa treatment group (herbal + chemotherapy) at control group (chemotherapy only). Ang treatment group ay may 34 (kung saan 15 ay lung cancer, stage IIIb 6, stage IV 9; 10 ay colon cancer, stage III 2, stage IV 8; 9 ay breast cancer, lahat ay stage IV; may 1 metastasis 13, two or more metastases 15). Ang control group ay may 27 (lung cancer 13, stage IIIb 5, stage IV 8; colon cancer 7, stage III 2, stage IV 5; breast cancer 7, lahat ay stage IV; may 1 metastasis 9, two or more metastases 11). Lahat ng pasyente ay first-time treatment 12, repeat treatment 49. Walang malaking pagkakaiba sa clinical data ng dalawang grupo (P>0.05), na may comparable characteristics.
Ang dalawang grupo ay ginamit ang regular chemotherapy protocol. Para sa lung cancer, ang Nabiximab plus cisplatin ang pangunahin; para sa colon cancer, ang cisplatin plus 5-fluorouracil plus leucovorin calcium; para sa breast cancer, ang paclitaxel plus epirubicin. Ang treatment group ay nagsimula ng pag-inom ng qi-tonifying and blood-activating formula (Yiqi Xiaoxia Granule) mula sa unang chemotherapy cycle: Astragalus 50g, Atractylodes 10g, Angelica 10g, Ligusticum 10g, earthworm 10g, Curcuma 20g, purple grass 20g.
Base sa World Health Organization's clinical efficacy standards for solid tumors [complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD)], ang mga pasyente ay nireview ng imaging before and after two cycles of treatment. Ang resulta ay nagpapakita na ang treatment group ay may PR 12 (36.4%), SD 17 (51.5%), PD 4 (12.1%); ang control group ay may PR 2 (7.4%), SD 18 (66.7%), PD 7 (25.9%). May malaking pagkakaiba sa epekto (P<0.05). Ang treatment group ay may 1 case na may CR sa pleural effusion.
Para sa duration of tumor survival, ang treatment group ay may average ng (20.73±20.02) months, ang control group ay may (11.93+5.08) months. May malaking pagkakaiba sa 24-month survival rate (P<0.05).
Para sa weight change, ang treatment group ay may 6 (17.6%) na umunlad (weight increase >2kg, sustained for over 4 weeks), 23 (67.6%) na stable (change within 2kg), 5 (14.7%) na bumaba (weight decrease >2kg, sustained for over 4 weeks); ang control group ay walang umunlad, 20 (74.1%) na stable, 7 (25.9%) na bumaba. Walang malaking pagkakaiba.
Para sa physical status, ang treatment group ay may 6 (17.6%) na nagbago (ECOG grade decreased), 23 (67.6%) na stable, 5 (14.7%) na bumaba (ECOG grade increased); ang control group ay may 20 (74.1%) na stable, 7 (25.9%) na bumaba. Ang physical status ng treatment group ay nagbago nang malaki, may malaking pagkakaiba sa control group (P<0.01).
Ang laboratory test ay nagpapakita na dahil sa regular use ng leukocyte-stimulating agents at hepatoprotective drugs, ang mga pasyente ay may normal na white blood cells at platelets. Ang hemoglobin na abnormally low before and after treatment ay 7 (20.6%) at 17 (50.0%) sa treatment group, 4 (14.8%) at 13 (48.1%) sa control group—walang malaking pagkakaiba. Pagkatapos ng treatment, ang treatment group ay may 1 (2.9%) na abnormal ALT, ang control group ay may 8 (29.6%) na abnormal—may malaking pagkakaiba (P<0.05); ang AST ay abnormal sa 4 (11.8%) sa treatment group, 4 (14.8%) sa control group; ang blood urea nitrogen ay abnormal sa 1 (2.9%) sa treatment group, 4 (14.8%) sa control group—walang malaking pagkakaiba. Ang comparison ng changes sa qi deficiency symptoms ay nagpapakita na ang treatment group ay may mas mababang sintomas tulad ng sweating, shortness of breath, lack of energy, fatigue, habang ang control group ay hindi nagbago o bumaba. Ayon sa Tsino medicine, "when vital energy is present inside, evil cannot invade," and "where evil gathers, there must be deficiency of vital energy"—this applies to tumor development as well. Due to deficiency of vital energy, external pathogens remain, meridians become blocked, and blood stasis leads to swelling. The researchers targeted the common qi deficiency and blood stasis in late-stage cancer patients, and modified the classic formula Bu Yang Huan Wu Tang into the Yiqi Xiaoxia Fang, increasing the amount of Huangqi to 50g as the primary herb. They added Bai Zhu to enhance the qi-tonifying and spleen-strengthening effect of Huangqi. Huangqi tonifies qi, while E Zhu resolves stasis; together they tonify without stagnation, making vital energy stronger and enhancing the body’s ability to eliminate masses. Zi Cao replaced Chi Shao, with similar properties but with anti-tumor effects, enhancing cooling blood, detoxifying, resolving masses, and relieving pain. Dang Gui, Chuan Xiong, and Di Long work synergistically with E Zhu to activate blood and resolve stasis. At the same time, Zi Cao’s cold nature counterbalances the warmth of Huangqi and Bai Zhu, making the formula balanced, combining tonification and elimination. Clinical observations indicate that the qi-tonifying and blood-activating approach not only improves efficacy and reduces chemotherapy side effects but also improves qi deficiency symptoms, enhances physical condition, improves quality of life, and prolongs tumor survival time.
|
